Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis.
Filippini G, Minozzi S, Borrelli F, Cinquini M, Dwan K.
Cochrane Database Syst Rev. 2022 May 5;5(5):CD013444. doi: 10.1002/14651858.CD013444.pub2.
PMID:35510826
The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression.
Effect of Minocycline on Depressive Symptoms in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Hellmann-Regen J, Clemens V, Grözinger M, Kornhuber J, Reif A, Prvulovic D, Goya-Maldonado R, Wiltfang J, Gruber O, Schüle C, Padberg F, Ising M, Uhr M, Friede T, Huber C, Manook A, Baghai TC, Rupprecht R, Heuser I.
Validity of evaluation scales for post-stroke depression: a systematic review and meta-analysis.
Liu F, Gong L, Zhao H, Li YL, Yan Z, Mu J.
BMC Neurol. 2024 Aug 15;24(1):286. doi: 10.1186/s12883-024-03744-7.
PMID:39148052
Uric Acid as a Biomarker for Mood Disorders: A Comparative Study of Blood Uric Acid Levels Correlating With the Symptom Severity and Treatment Response.
Immanuel S, Kaki A, Jetty RR, Vupputuri SM, K V R, R AS.
Cureus. 2024 Aug 13;16(8):e66784. doi: 10.7759/cureus.66784. eCollection 2024 Aug.